The Nordic Biologics Talent War
How Denmark and Sweden Are Competing for 3,000+ Manufacturing Professionals - and What It Means for the Future of Biologics Production
FUJIFILM Diosynth needs to hire 1,000+ employees in Hillerød. Novo Nordisk requires 800 workers for its Kalundborg expansion. AGC Biologics doubled its Copenhagen workforce. PolyPeptide is scaling Malmö operations. All simultaneously. All competing for the same talent pool.
The Nordic biologics investment boom has created an unprecedented workforce challenge: how do you scale manufacturing operations by 50-100% when the regional labour market has never before needed this many bioprocess engineers, quality specialists, and regulatory professionals?
The Nordic talent situation contains a striking paradox: whilst FUJIFILM, AGC, and PolyPeptide aggressively hire, Novo Nordisk simultaneously announced a global restructuring of 9,000 positions in 2025.
This creates complex dynamics:
Displaced Novo Nordisk employees become recruitment targets
Manufacturing professionals affected by Novo's restructuring possess exactly the GLP-1 and biologics expertise competitors seek.
Wage inflation accelerates
Competition for experienced talent drives compensation premiums, particularly for specialised roles like QC analytical chemists and regulatory affairs managers.
Knowledge transfer creates IP concerns
Former Novo employees joining competitors bring GLP-1 manufacturing knowledge, creating intellectual property and competitive intelligence sensitivities.
Regional loyalty shifts
Denmark's pharmaceutical sector has traditionally been synonymous with Novo Nordisk. The emergence of FUJIFILM, AGC, and others as major employers diversifies career options and reduces company-specific dependence.
Unable to fill 1,000+ positions from Denmark's domestic labour market alone, FUJIFILM Diosynth Hillerød has recruited across 70+ nationalities—creating Europe's most internationally diverse biologics manufacturing workforce.
The Recruitment Strategy
- Targeted recruitment in Central/Eastern Europe (Poland, Romania, Hungary)
- Aggressive hiring from Southern Europe (Spain, Italy, Portugal)
- Global outreach to Asia-Pacific and North America for specialised roles
- Partnership with Danish immigration authorities for streamlined visa processing
The Support Infrastructure
Successfully integrating 70+ nationalities requires comprehensive support:
- Relocation assistance (housing, schools, partner employment)
- English as working language (99%+ Nordic professionals fluent)
- Cultural integration programmes
- Danish language classes for long-term residents
This international model demonstrates a critical lesson: Nordic biologics expansion is only possible because Denmark and Sweden actively recruit globally. Domestic labour markets alone cannot support the growth trajectory.
Current Capacity
- Technical University of Denmark (DTU): ~250 bioengineering graduates/year
- University of Copenhagen: ~200 pharmaceutical sciences graduates/year
- Uppsala University: ~300 biotechnology/pharmaceutical graduates/year
- Lund University: ~150 chemical engineering/biotech graduates/year
Combined output: ~900 graduates/year
Industry demand: 3,150+ new positions over three years = ~1,050/year
The gap is clear: even if 100% of relevant graduates entered biologics manufacturing (unrealistic), domestic universities cannot meet demand.
University Response Strategies
- Expanding enrolment in bioprocess engineering programmes
- Creating industry-sponsored master's programmes (e.g., Novo Nordisk Fellowships)
- Developing apprenticeship and dual-study programmes
- Partnering with manufacturers for on-site training facilities
- Recruiting international students who may remain post-graduation
Faced with persistent talent shortages, Nordic manufacturers are accelerating automation adoption—not just to improve efficiency, but to fundamentally reduce workforce requirements.
Technologies Deployed
- Automated sampling and analytics
Eliminates manual sample collection, reducing QC staffing needs by 30-40%
- Robotic process automation for buffer preparation
Reduces operator requirements whilst improving consistency
- AI-driven process control
AstraZeneca Södertälje implementing Benchling for digital lab workflows
- Digital twins for process optimisation
AGC Biologics Copenhagen building virtual models with Novonesis
- Autonomous mobile robots (AMRs) for materials handling
Reduces logistics personnel requirements in large facilities
The impact: New Nordic facilities are designed from the ground up for 20-30% lower headcount per unit of production compared to legacy sites, purely through automation.
Whilst precise salary data is limited, Nordic biologics compensation is trending upward:
Estimated Salary Ranges (Denmark, 2025)
- Manufacturing operator (entry level): DKK 350,000-450,000 (£40,000-52,000)
- Process engineer (3-5 years): DKK 550,000-700,000 (£63,000-80,000)
- Senior QC analyst: DKK 600,000-750,000 (£69,000-86,000)
- Regulatory affairs manager: DKK 750,000-950,000 (£86,000-109,000)
- Manufacturing site director: DKK 1,200,000+ (£138,000+)
Compensation premiums observed:
- 15-25% premium for GLP-1 manufacturing experience
- 20-30% premium for candidates willing to relocate internationally
- 10-20% premium for immediate availability (vs. notice period)
Accelerated career progression
Rapid expansion creates leadership opportunities unavailable at mature organisations
Cross-functional development programmes
Rotations between QC, production, and process development build versatile skillsets
Equity and profit-sharing schemes
Particularly common at CDMOs like FUJIFILM and AGC to compete with Novo Nordisk stock options
Work-life balance emphasis
Nordic culture's focus on flexible hours and family leave as differentiator vs. UK/US competitors
State-of-the-art facilities
New Nordic sites offer latest technology, contrasting with legacy facilities elsewhere
1. Geographic Expansion Requires Workforce Strategy First
FUJIFILM's success in Denmark demonstrates that workforce availability must drive site selection as much as logistics or tax incentives. Sites in talent-rich regions (university hubs, existing pharma clusters) enable faster ramp-up.
2. International Recruitment Is Non-Negotiable for Rapid Scale
Even Denmark—with strong educational infrastructure and pharmaceutical heritage—cannot fill 1,000+ positions domestically. Manufacturers must build global recruitment capabilities and immigration partnerships.
3. Automation Becomes Strategic Workforce Solution
Persistent talent shortages are accelerating automation adoption beyond pure efficiency gains. Manufacturers are redesigning processes to reduce headcount requirements, making automation a workforce strategy, not just an operations improvement.
4. Academic Partnerships Need Years to Bear Fruit
University programme expansions take 3-5 years to produce graduates. Manufacturers facing immediate needs cannot rely on academic pipeline—they must recruit experienced talent and provide internal training.
5. Compensation Arms Races Erode Regional Cost Advantages
Intense competition for talent is driving Nordic biologics salaries toward Western European/US levels, potentially eroding Denmark and Sweden's historical cost advantages. Sustainability and quality must increasingly justify premium labour costs.
The Nordic biologics boom has revealed a fundamental constraint: talent availability, not capital or manufacturing technology, limits expansion speed.
Despite $15 billion+ in investment and aggressive construction timelines, manufacturers struggle to fill 3,150+ positions across just three years. FUJIFILM's 70+ nationality workforce, Novo Nordisk's simultaneous restructuring and expansion, and accelerating automation adoption all underscore the same challenge: finding, hiring, and retaining qualified biologics manufacturing professionals is the bottleneck.
For pharmaceutical companies considering Nordic expansion, workforce strategy must be addressed before ground is broken. This means:
- Partnering with universities years before hiring begins
- Building international recruitment capabilities and immigration partnerships
- Designing facilities for automation from day one to reduce headcount
- Creating competitive compensation packages that reflect talent scarcity
- Developing robust retention programmes to protect the investment in hiring
The Nordic talent war is far from over. As FUJIFILM, Novo Nordisk, AGC, PolyPeptide, and others continue expanding, competition will only intensify. The winners will be those who treat workforce development as strategically as they treat facility construction and process development.
Because in the end, manufacturing capacity is only valuable if you have people capable of running it.
